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E-mail address: r.p.coppes@umcg.nl (R.P. Coppes).Background and purpose: In this study, we investigated whether cancer stem cell marker expressing cells
can be identiﬁed that predict for the response of esophageal cancer (EC) to CRT.
Materials and methods: EC cell-lines OE-33 and OE-21 were used to assess in vitro, stem cell activity, pro-
liferative capacity and radiation response. Xenograft tumors were generated using NOD/SCID mice to
assess in vivo proliferative capacity and tumor hypoxia. Archival and fresh EC biopsy tissue was used
to conﬁrm our in vitro and in vivo results.
Results: We showed that the CD44+/CD24 subpopulation of EC cells exerts a higher proliferation rate
and sphere forming potential and is more radioresistant in vitro, when compared to unselected or
CD44+/CD24+ cells. Moreover, CD44+/CD24 cells formed xenograft tumors faster and were often
located in hypoxic tumor areas.
In a study of archival pre-neoadjuvant CRT biopsy material from EC adenocarcinoma patients (N = 27),
this population could only be identiﬁed in 50% (9/18) of reduced-responders to neoadjuvant CRT, but
never (0/9) in the complete responders (P = 0.009).
Conclusion: These results warrant further investigation into the possible clinical beneﬁt of CD44+/CD24
as a predictive marker in EC patients for the response to chemoradiation.
 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 107 (2013) 434–441Esophageal cancer (EC) is an aggressive disease with increasing
incidence and a low curability rate [1–4]. In specialized centers, the
5-year survival after surgery for all stage groups together is only
20–40% [5,6]. Multimodality treatments with preoperative (neo-
adjuvant) irradiation in combination with chemotherapy (chemo-
radiation) have recently become common practice [7,8]. These
multimodality treatments achieve a gain in 5-year survival of only
10–15% [7,8]. However, a signiﬁcant proportion of 60–70% does not
respond well to these treatments and are thus unnecessarily expe-
riencing severe side-effects [7–9].
Factors predicting the response to neoadjuvant chemoradiation
that may identify the group of non-responders before treatment is
given [10]. This may help to reduce the number of unnecessarily
treated patients and lead to investigations on new and more effec-
tive therapies for this patient group.
Recently, evidence has accumulated that many solid tumors are
driven and managed by a small population of cancer stem cells
(CSCs), tumor-initiating cells or cancer stem cell like cells [11–d Ltd. All rights reserved.
oningen, University Medical
ius Deusinglaan 1, 9713 AV15], which may be more resistant to treatment [16,17]. It is postu-
lated that in most cases, these CSCs are, in part, responsible for the
inadequate treatment response of certain tumors [16–19]. It is
therefore of great importance for the radiation oncology ﬁeld to
intensify research into CSCs, which could be complimentary to
yet established or to be investigated predictive factors for the re-
sponse to radiotherapy [20–23].
More research is necessary into what extent CSCs are present in
EC and what would be their response to radiotherapy [24,25]. In
several models for cancers, cell surface markers have been used
to identify CSCs such as CD133, CD44, CD24, CD90, CD326 (Epcam)
and combinations here of [11,13,14,16,26–28]. These proteins of-
ten activate tumor-speciﬁc, downstream pathways and may there-
fore be possible targets for further therapy [12,14,26,29,30].
In this study, we hypothesized that a subpopulation of cells may
exist in EC that could predict for treatment resistance. Hereto, we
tested CSC marker expression, in vitro growth of spheroids, radia-
tion sensitivity, and in vivo growth of several EC derived cell lines
derived sub-populations. In EC, a putative CSC-like population was
identiﬁed with superior in vitro and in vivo growth as well as in-
creased radiation resistance on the basis of CD44 and CD24 expres-
sion. In patient material the same markers could be detected which
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sponse in a clinical setting.
Methods
For details see supplementary methods section.Cell culture
The OE-33 cell-line derived from a poorly differentiated Barrets
adenocarcinoma of the lower esophagus and the OE-21 cell-line
derived from a squamous cell carcinoma of the upper esophagus
were cultured under standard conditions with RPMI 1640 growth
medium supplemented with 10% fetal calf serum, 1% penicillin/
streptomycin in a humidiﬁed atmosphere and 5% CO2 at 37 C.
Cells were passaged at 50–80% conﬂuence [31]. Both cell-lines
were independently DNA authenticated by the Leibniz Institute
DSMZ-German Collection of Microorganisms and Cell Cultures
(Braunschweig, Germany). Serum-free and low adherent growing
conditions (ultra-low adherent plates, Corning Inc., Corning, New
York, USA) were employed to grow the cells as spheroids using
neural basal A medium containing N2, bFGF and FGF-2 as previ-
ously described by Vermeulen et al. [14].Flow cytometry
Single cell suspensions obtained from tumor tissue or cell-lines
were resuspended in PBS with 0.2% bovine serum albumin (BSA).
Primary ﬂow cytometric antibodies were: CD44-PE (BD Biosci-
ences, Franklin Lakes, New Jersey, USA), CD24-FITC (BD Biosci-
ences, Franklin Lakes, New Jersey, USA), EPCAM-Alexa ﬂuor 647
(eBioscience, San Diego, California, USA), CD133/1-APC (BergischFig. 1. Selection of candidate subpopulation. (A) Quantiﬁcation of CD44+/CD24 phenoty
95% conﬂuent cells in the OE-33 cell line P < 0.001 analyzed with the ﬂowcytometer (
standard deviation. (B) Quantiﬁcation of FACS analysis of digested spheres harvested at d
experiments are shown. Error bars represent the standard deviation. (C) Quantiﬁcation o
independent experiments (NP 3). Error bars represent the standard error. (D) Sphere
representative of at least 4 independent experiments (NP 4). Error bars represent the sGladbach, Germany), CD29-PE (BD Biosciences, Franklin Lakes,
New Jersey, USA), CD-90-FITC (eBioscience, San Diego, California,
USA). Flow cytometric analysis was performed on the FACS-Calibur
(BD Biosciences, Franklin Lakes, New Jersey, USA) or LSR-II (BD Bio-
sciences, Franklin Lakes, New Jersey, USA). Flow cytometric data
were analyzed using Flojo version 7.6 software (Treestar Inc., Ash-
land, Oregon, USA). To isolate cells with a putative stem cell pheno-
type cell sorting was performed using a MoFlo-XDP or
MoFLoAstrios cell sorter (Beckman Coulter previously DakoCyto-
mation, Glostrup, Denmark).In vitro radiation experiments, clonogenic assays
Sorted single cell suspensions of the different subpopulations
obtained after ﬂow-cytometric sorting were counted and plated
immediately in standard growth medium (RPMI, see cell culture
section). Cells were allowed to attach overnight and (sham) irradi-
ated (Cesium 137, IBL) with 0, 2, 4 and 6 Gy at a dose rate of
0.65 Gy/min. After irradiation cells were trypsinized, replated and
concentrations were adjusted according to the expected survival.
Colonies were allowed to grow for 10–14 days, ﬁxated and stained
(coomassie brilliant blue). Surviving fractions were determined by
dividing the average number of colonies at different doses by the
average number of colonies in the non-irradiated control.Animal experiments
Female NOD/SCID mice were purchased from the Harlan labora-
tories (NOD.CB17-Prkdcscid/NCrHsd). Mice were subcutaneously
injected with tumor cells in a 1:1 suspension with matrigel (BD
Biosciences, Franklin Lakes, New Jersey, USA) under general
anesthesia (isoﬂurane 2.5%). A total of 1.5  105 OE-21 cells orpe (CSC-phenotype) expression in day 4 spheroid cells and 15–30% conﬂuent vs 90–
FACS). Data represent at least two independent experiments. Error bars represent
ifferent time points for the expression of CD44 and CD24, data of two independent
f the average colony size of OE-33 after 13 days in culture, data represent at least 3
forming capacity of OE-33 after 4 days in serum-free culture conditions, data are
tandard deviation. Abbreviations: CF = conﬂuence.
Fig. 2. CD44+/CD24 phenotype displays aggressive tumor growth in vivo. (A) Growth curves of xenograft tumors generated in NOD/SCID mice of OE-33 cell-line after
sorting for CD44+/CD24 and CD44+/CD24+ subpopulations for ﬁrst generation tumors, data represent at least 3 independent experiments. Error bars represent the standard
error. (B) Growth curves of xenograft tumors generated in NOD/SCID mice of OE-21 cell-line after sorting for CD44+/CD24 and CD44+/CD24+ subpopulations for ﬁrst
generation tumors. One CD44+/CD24+ and one of the unsorted mice did not produce a tumor, therefore N = 2 was compared with N = 3 of the CD44+/CD24 tumors. Error
bars represent the standard error. (C) Quantiﬁcation of FACS analysis of single cells obtained from the OE-21 xenograft tumors in all generations (1st–3rd). The CD44+/CD24
expression was analyzed for correlations with growth speed using the pearson correlation coefﬁcient. (D) Squamous cell carcinoma OE-21 cell-line was generated by injecting
the CD44+/CD24 subpopulation in NOD/SCID mice (left). With increasing generation number (from left to right); Second generation tumor was generated by injecting single
cells from a ﬁrst generation tumor. A third generation tumor was generated by injecting single from a second generation tumor.
436 Predicting of response in esophageal cancer6.0  105 OE-33 cells were injected for tumor generation. Single cells
were obtained by using a modiﬁed method from a previously pub-
lished study on salivary glands [32]. In selected cases, mice were
intraperitoneally injected with pimonidazole HCI 60 mg/kg (Hydrox-
yprobe™-1, NPI, Inc., Burlington, Massachusetts, USA) as a marker for
hypoxia. It is important to note that between 1st and 2nd generation
and 2nd and 3rd generation tumors, the cells were not resorted for
either CD44+/CD24 or CD44/CD24+ subpopulations.
All animal experiments were performed according to our insti-
tutional animal ethics guidelines and were reviewed by an animal
ethics committee.Human tissue samples experiments
Human tissue biopsies were obtained from patients with
conﬁrmed histological diagnosis of esophageal cancer during
routine staging with gastrointestinal endo-echography (EUS) or
from rest material after surgical resection of the tumor with in-
formed consent. Tissue samples were immediately placed in
phosphate buffer with antibiotics and antimycotics. In the lab,
the tissue was washed and incubated for at least 4 h in RPMI
with antibiotics and antimycotics and subsequently dissociated
into single cells, as described above. The single cells obtained
after this process were used for direct FACS analysis (Fig. S3
for gating strategy).
All human tissue collection experiments were reviewed by the
institutional human ethics commission (Institutional board re-
view). The ethics guidelines comply with the Helsinki declaration
on experiments with humans.Immunohistochemistry and immunoﬂuoresence imaging
Immunohistochemical staining was performed on 5 lm tissue
sections from archival patient material or tumor xenografts using
primary antibodies against CD44 (Biolegend, San Diego, California,
USA), CD24 (Santa Cruz Biotechnologies Inc., Santa Cruz, California,
USA) and pimonidazole (J.A. Raleigh, Department of Radiation
Oncology and Toxicology, University of North Carolina, Chapel Hill,
North Carolina, USA) in parafﬁn [33] or frozen sections [34].
Quantiﬁcation of CD44+/CD24 population in patient biopsy sam-
ples was performed as follows: ﬁrst, the serially stained sections with
CD44 and CD24, were scored blindly by an experienced pathologist
(H.H.). In cases with both CD44 and CD24 positivity, the pathologist
scored for the presence of tumor areas that were CD44+/CD24. Fur-
thermore, when only single positivity of CD44 was seen, these cases
were obviously considered as CD44+/CD24 cases. Cases with single
positivity for CD24were considered asnot havingCD44+/CD24. Both
CD44 andCD24 resultswere based exclusively onmembrane staining.
Statistical analysis
Experiments are representative of at least 3 experiments unless
otherwise stated. All data are presented as mean and ±SD/SEM.
Groups were compared with the student’s t test. Correlations were
determined with the Pearson’s bi-variant comparison.
Results
To identify progenitor cell markers on subpopulations in EC cell
lines (OE-33 and OE-21), it was analyzed whether these markers
Fig. 3. CD44+/CD24 cells are present in hypoxic areas in vivo. (A) Pseudo-colored, composite image after multiple immunoﬂorescent staining and scanning at 10 of an OE-
21 tumor. Red = CD44 (left)/CD24(right), green = pimonidazole, blue = dap. Arrow denotes the CD44+/CD24 areas which are located in hypoxic regions (CD44+/CD24/
pimonidazole+). (B) Pseudo-colored, composite image after multiple immunoﬂorescent staining and scanning at 10 of another OE-21 tumor. Red = CD44 (left)/CD24(right),
green = pimonidazole, blue = dap. Arrow denotes the CD44+/CD24 areas which are located in hypoxic regions (CD44+/CD24/pimonidazole+).
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CD29 and CD133 were not present at the surface of OE-33 or OE-
21 cells, whereas CD326 (EpCam) was expressed ubiquitously
(Supplementary Table 1 and Fig. S2). Interestingly, a subpopulation
of CD44+/CD24+ and CD44+/CD24 of different sizes could be
identiﬁed in both the OE-33 and the OE-21 cell line (Supplemen-
tary Table 1 and Fig. S2). Since cancer cells growing in non-adher-
ent conditions are less likely to differentiate than cells growing in
adherent conditions with serum [11,13,16,35], we investigated
whether the expression of CD44 and CD24 was dependent on cul-
ture conditions. Approximately 40% (44.5 ± 7.9%) of OE-33 cells
growing sparsely at 15–30% conﬂuency were CD44+ but CD24,
whereas in cells growing at 90–95% conﬂuence only 3.6 ± 2.3%
were CD44+/CD24 (P = 0.010, Fig. 1A and Fig. S1). Moreover, in
non-adherent serum free growing conditions OE-33 cells formed
spheroid structures (Fig. S1) that expressed CD44+/CD24 in
59.3 ± 2.1% of the cells (Fig. 1A and Fig. S1). These results indicate
that in OE-33, the CD44+/CD24 expression is dependent on the
culture conditions. Next, it was assessed whether this shift from
a high percentage of cells expressing CD44+/CD24 to lower per-
centages was observed after prolonged spheroid culture condi-
tions. Indeed, a gradual shift from a predominantly CD44+/
CD24 phenotype toward the CD44+/CD24+ phenotype was found
in time concomitant with increasing sphere size (P = 0.019 and
P = 0.020, Fig. 1B). To test for differences in proliferative potential,
FACS sorted cell populations were allowed to grow into colonies
and CD44+/CD24 cells formed larger adherent colonies after
13 days in culture compared to unsorted cells or CD44+/CD24+
cells (P < 0.001 and P = 0.020, Fig. 1C and Fig. S1). In spheroid 3Dcultures, FACS sorted CD44+/CD24 cells showed a 2.2-fold higher
sphere forming capacity compared with the CD44+/CD24+ cells
(P = 0.014, Fig. 1D). Taken together, these results suggest that in
OE-33 CD24 may develop into CD24+ cells in prolonged in vitro
sphere culture. Under adherent conditions, cells that lack CD24
expression (within CD44+ cells) may represent a more progenitor
like population with higher proliferative capacity.
It has been postulated that cancer cell subpopulations that are
enriched with cancer progenitor cells form xenograft tumors more
easily and grow more aggressively [11,13,17,26,36]. Therefore, the
NOD/SCID mouse model was used to assess the in vivo tumor form-
ing ability of both the OE-33 and OE-21 cell-lines. Animals were sub-
cutaneously injected with unsorted cells or FACS sorted cell
suspensions (CD44+/CD24 or CD44+/CD24+). Tumor growth was
accurately monitored. After 9 weeks the tumor volumes formed by
CD44+/CD24 OE-33 cells were much larger (433 ± 127 mm3) when
compared to tumors formed by CD44+/CD24+ (131 ± 59 mm3,
P = 0.020) and unsorted (187 ± 104mm3, P = 0.062) cells (Fig. 2A).
Similarly, tumors derived from OE-21 CD44+/CD24 cells grew fas-
ter and were larger after 6 weeks (733 ± 81 mm3) when compared
with tumors grown from CD44 + CD24+ (301 ± 151 mm3,
P = 0.023) and unsorted cells (383 ± 174 mm3, P = 0.050) (Fig. 2B).
The tumor take rates were 3 out 3 for OE-33 in all 3 cell compart-
ments. In OE-21 the take rates were 3 out of 3 for CD44+/CD24
and 2 out of 3 for both CD44+/CD24+ and unsorted cells.
To further assess which cell fraction determines tumor growth
rate, FACS analysis was performed on single cell suspensions ob-
tained from ﬁrst, second, and third generation tumors. Since the
OE-33 tumors had slower in vivo growth rates compared to
Fig. 4. CD44+/CD24 is more resistant to radiotherapy. (A) Clonogenic survival assay with corresponding dose-response curves of the OE-33 cell line sorted for the CD44+/
CD24 and CD44+/CD24+ phenotypes, data represent 4 independent experiments (NP 4). (B) Bar chart of clonogenic survival assay of Fig. 5A at 6 Gy. Error bars represent
the standard deviation. (C) Clonogenic survival assay with corresponding doses-response curves of the OE-21 cell line sorted for the CD44+/CD24 and CD44+/CD24+
phenotypes, data represent 3 independent experiments (NP 3). (D) Bar chart of clonogenic survival assay of Fig. 5C at 6 Gy. Error bars represent the standard deviation.
438 Predicting of response in esophageal cancerOE-21 tumors, serial transplant experiments were performed only
with OE-21.In the 2nd and 3rd tumors, the size of the CD44+/
CD24 or CD44+/CD24+ populations were analyzed and correlated
with growth rate. The proportion of CD44+/CD24 cells correlated
strongly with in vivo growth rate (R2 = 0.66, P = 0.025) (Fig. 2C),
whereas CD44+/CD24+ showed an inverse correlation with the
in vivo growth speeds (R2 = 0.38, P = 0.238) (Fig. S4). The average la-
tency for CD44+/CD24 derived tumors was 32 ± 12 days and
44.5 ± 21 days for CD44+/CD24+ derived tumors (P = 0.265). The
average doubling time between the volumes 100 mm3 and
400 mm3 was 7.9 ± 2.4 days for CD44+/CD24 and 9.3 ± 5.9 days
for CD44+/CD24+ derived tumors (P = 0.079). Importantly, the OE-
21 cells grew into tumors, whichweremorphologically very similar
to primary human esophageal tumors in all three generations, as
determined by an experienced pathologist (HH) (Fig. 2D). More-
over, these tumors were of the squamous-cell carcinoma subtype
classiﬁed according to the Union for International Cancer Control
TNM 7th edition guidelines [37]. Overall, the in vivo growth exper-
iments point toward a more proliferative and more aggressive phe-
notype of the CD44+/CD24 subpopulation.
Resistance to hypoxia is considered to be a characteristic of pro-
genitor and radioresistant cancer cells [38–40]. To investigate
whether CD44+/CD24 or CD44+/CD24+ cells reside in the so
called ‘‘hypoxic niche’’ and if these cells can grow under such hyp-
oxic conditions in vivo, hypoxic areas were immunohistochemi-
cally deﬁned using pimonidazole as a marker for hypoxia.
Sections were analyzed blindly to test the hypothesis that
CD44+/CD24 cells are able to reside in hypoxic areas within the
tumor. A proportion of CD44+/CD24 cells were located near or
in hypoxic areas, whereas CD44+/CD24+ cells were never observedin hypoxic areas in (Fig. 3). These data might indicate that CD44+/
CD24 cells, growing in vivo, are resistant to hypoxia compared to
CD44+/CD24+ cells. The relevance of this needs to be further
determined.
To test whether the CD44+/CD24 population may be used to
predict the response to radiation, their sensitivity for radiation
was compared to CD44+/CD24+ and unsorted cells (15). To this
end, an in vitro clonogenic assay was used. After a dose of 6 Gy
the OE-33 cell line showed a signiﬁcantly higher survival for the
CD44+/CD24 subpopulation compared to the CD44+/CD24+
(P = 0.036) fraction and unsorted fraction (P = 0.033) (Fig. 4A and
B). In the OE-21 cell line, also a signiﬁcantly higher survival for
the CD44+/CD24 subpopulation was observed when compared
with the CD44+/CD24+ subpopulation (P = 0.017) and unsorted
fractions at 2 Gy (Fig. 4C) and 6 Gy (P = 0.020) (Fig. 4C and D).
These results indicate that cells with the CD44+/CD24 phenotype
are more radioresistant than cells with the CD44+/CD24+ pheno-
type and unselected OE-21/OE-33 cells.
The in vitro and in vivo experiments indicate that the CD44+/
CD24 phenotype may be an interesting marker combination for
the prediction of response to radiotherapy. One important deter-
minant for clinical use is that the phenotype can be identiﬁed in
fresh tumor tissue [13,28]. Therefore, we prospectively analyzed
freshly obtained tumor material from 8 different patients, suffering
from carcinoma of the distal esophagus, for CD44 and CD24
expression (Fig. 5A and Fig. S3). Although the proﬁles for CD44
and CD24 were very variable, in most cases a distinct CD44+/
CD24 and CD44+/CD24+ subpopulation could be identiﬁed.
To test for a correlation between the CD44+/CD24 marker
combination and the response to neoadjuvant chemoradiation in
Fig. 5. The CD44+/CD24 subpopulation can be prospectively identiﬁed in human material and is a predictor of response to neoadjuvant chemoradiation. (A) FACS plots of
prospectively isolated patient material analyzed for CD44 and CD24 marker expression. (B) Light microscope image of an esophageal adenocarcinoma pre-treatment biopsy
serial section stained for CD24 and CD44, at 20magniﬁcation. The arrows point to the cancer cells which are CD44+/CD24. The patient had no response to the neoadjuvant
chemoradiation.
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gated for CD44 and CD24 expression using immunohistochemistry.
From a database in our institution 27 patients who received neoad-
juvant chemoradiation were randomly selected. All 27 patients had
non-diffuse intestinal type adenocarcinoma of the esophagus.
Eighteen patients (N = 18) were determined to have vital tumor
(morphologically intact tumor cells) after pathological assessment
of the surgical specimen, and 9 patients had no vital tumor tissue
after the neoadjuvant chemoradiation. From the patients with vital
tumor tissue, 9 out of 18 patients (50%) showed the presence of
CD44+/CD24 cells in the pre-treatment biopsy specimen,
whereas CD44+/CD24 cells were never found in patients without
vital tumor (0/9:0%) (Table 1, P = 0.009). The 9 patients with
CD44+/CD24 cells in their biopsy samples could not be further
distinguished from the other 9 patients with vital tumor tissue,Table 1
Immunohistochemistry results for staining of esophageal cancer pre-treatment biopsy tiss
After neoadjuvant chemoradiation
Marker/clinicopathologic factor Vital tumora (N = 18)
CD44+ 72% (N = 13)
CD24+ 50% (N = 9)
CD44+/CD24 50% (N = 9)
cT-stageb (T1/T2/T3/T4) 0%/6%/88%/6%
cN-stagec (N0/N1) 39%/61%
Histology Intestinal type AC 100%
Histological grade (1/2/3/4)d 6%/61%/33%/0%
AC: adenocarcinoma.
a Morphologically intact tumor cells.
b Pre-treatment T-stage.
c Pre-treatment N-stage.
d Pre-treatment histological grade according to the 4-tier system.using regression grades. In Fig. 5B one of the CD44+/CD24 areas
is visible in a pre-treatment biopsy specimen from a non-respon-
der patient. In Table 1, the results of the CD44 and CD24 staining
and pathological characteristics of all 27 patients are shown. Thus
in this preliminary study, the presence of CD44+/CD24 cells in EC
pre-treatment biopsy tissue indicates a lack of response to
chemoradiation.
Discussion
This study proposes that cells with a CD44+/CD24 phenotype
are more proliferation prone, grow more aggressively, reside in the
radioresistant hypoxic niche and are a radioresistant subset in EC
cell lines. In patient samples, a similar population was found
that identiﬁed a group of patients with a lack of response to CRT.ue in 27 patients.
No vital tumora (N = 9) P-value
33% (N = 3) 0.053
89% (N = 8) 0.049
0% 0.009
0%/0%/88%/12% 0.687
12%/88% 0.136
Intestinal type AC 100% 1.000
0%/88%/12%/0% 0.317
440 Predicting of response in esophageal cancerTherefore, the presence of CD44+/CD24 cells may predict for the
(lack of response to (chemo) radiotherapy in esophageal carcinoma
patients and can have a negative impact on the survival using
current therapies. Identiﬁcation of these new markers for esopha-
geal cancer is essential, because these factors make it possible to
identify patients that do not beneﬁt from current therapies.
Previous clinical data show a clear survival disadvantage for pa-
tients that had hardly any response to the neoadjuvant chemora-
diotherapy, after pathologic evaluation of the resection specimen
(according to standard pathologic guidelines) [41,42]. This may
be caused by a treatment resistant sub-population of tumor cells.
It has been suggested that each tumor contains cells with stem
cell-like characteristics (cancer stem cells (CSC)), which are resis-
tant to therapy and drive tumor regrowth [16–18]. But the exact
CSC or normal stem cell in EC and the esophagus remains elusive
[25,43]. Research into the CD44 status has been performed previ-
ously by Takaishi et al. [18] on gastric cancer tissue, which has a
close tumor-biological relation to esophageal cancer. In this study,
it was shown that the CD44 positive subfraction selects for more
chemoradiation resistant cells. Another study by Winder et al.
[44] also demonstrated that CD44 positivity correlates with a re-
duced survival in gastric cancer patients. Furthermore, a recent
study in laryngeal cancer patients showed that CD44 predicted
for a higher chance on local recurrences (a clinical surrogate for re-
sponse assessment) [45]. Interestingly in line with our results, also
in esophageal squamous cell carcinoma it was shown that, CD44
correlates with increased therapy resistance and aggressive tumor
growth [46]. Our study revealed that in EC cell lines and tumor
biopsies the CD44 population can be subdivided into at least 2 sub-
populations with different characteristics. The CD44+/CD24 sub-
fraction of two EC cell lines displayed CSC-like characteristics and
were found to be highly proliferative, formed more and bigger
spheres, were less abundantly present in culture conditions that
induce differentiation and were more resistant to radiation when
compared to CD44+/CD24+ or unselected cells. Indeed, the
CD44+/CD24 subpopulation has previously been shown to select
for CSCs and chemoradiation resistant cells, in breast cancer cell-
lines and primary breast tumor tissue [11,16]. To translate our re-
sults into a clinical setting it was determined whether the CD44+/
CD24 subpopulation was present in primary EC material.
Although marker expression was rather heterogeneous, both the
CD44+/CD24 and CD44+/CD24+ subpopulations could be identi-
ﬁed in primary human EC. About half of the patients had a
CD44+/CD24 expression above 40%, which does not indicate a
rare primitive or stem cell like population. This suggests that addi-
tional markers may be required to have a more accurate estimation
of CSCs or therapy resistant cells. One possible candidate for this is
EPCAM, which from studies in colon cancer was shown to select for
CSCs in combination with CD44 [28] The biopsies in our study con-
tained a CD44+/CD24/EPCAM+ subpopulation of a much smaller
size, which would be more in line with the amount of CSCs in other
malignancies (Fig. S5) [17,26] .
In a pilot study performed on a historical sample of esophageal
cancer patients, the presence of CD44+/CD24 immunohistochem-
ically determined was predictive of the response to chemoradia-
tion. The expression of CD44 in our cell lines did not correlate
with detected expression in our primary biopsy archival material.
This can possibly be explained by the high selectiveness for aggres-
sive cells within the investigated cell-lines. However, the presence
in CD44+/CD24 cells in patient samples, either or not in combina-
tion with EPCAM, could be a signature for CSC cells in EC. But more
studies are needed to validate these results, like for instance limit-
ing dilution tumor-initiating experiments, and validation studies
on larger and/or prospective datasets. It seems obvious that this
is an inherent limitation of investigations with cancer cell-lines
and warrants caution for over-interpreting these results. This canbe overcome by performing tumorigenicity experiments with pri-
mary human esophageal cancer tissue. Unfortunately, we were
not able to grow tumors from isolated human cells. Others have
also reported the same problem [25] .
Detection of CSC markers in tumor biopsies could distinguish
patients that will not respond to the current therapies. For these
patients toxic treatments could be avoided providing a better qual-
ity of life, and warrant investigations into alternative treatment
options.
In conclusion, the CD44+/CD24 subpopulation is present in
primary EC material and possibly predicts a reduced response to
chemoradiation. CD44+/CD24 EC cells are more resistant to radi-
ation in vitro. Furthermore, CD44+/CD24 cells exhibit some CSC-
like characteristics such as increased growth in vivo and in vitro.
These results warrant further investigation into the possible clini-
cal beneﬁt of CD44+/CD24 in EC patients as a predictive marker
for the response to chemoradiation.Funding source
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GUIDE. The authors declare that the funding source was in no man-
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